Prof Toh Han Chong is Co-Founder and Chief Medical Officer Neotila Biosciences Inc. He is also Deputy CEO, National Cancer Centre Singapore (Strategic Partnerships) and Professor at Duke-NUS Medical School. He obtained his BSc from the University of London in infection and immunity and his medical degree from the University of Cambridge, UK. His oncology and research fellowships were at the Singapore General Hospital, Massachusetts General Hospital and Harvard Medical School, and at the Center for Cell and Gene Therapy, Baylor College of Medicine, US. Dr Toh is an alumnus of the Harvard Business School General Management Programme. He received the National Senior Clinician Scientist Award in 2017, the National Medical Excellence Award in 2018 and the National Medical Research Council STAR Award in 2022. He is a recipient of the National Clinician Scientist Award for his pioneering work in cell therapy for cancer. He conducted the first cancer vaccine and T cell therapy clinical trials in Singapore, and continues to work actively in the field of cancer immunotherapy, immunology and inflammation. He also had a strong interest in drug development for gastrointestinal cancers including colon and liver cancer. Dr Toh is an Associate Professor and College Master at the Duke-NUS Medical School. He is also an adjunct Principal Investigator at the Institute of Molecular and Cell Biology, A*STAR. He was a council member in the Singapore Medical Association and the Singapore College of Physicians. NeoTILa Biosciences is an early-stage biotech company focused on liver disease and cancer, particularly using computational biology and engineered immune-cell therapies to enable earlier detection and more precise treatment. Its stated vision is to combine computational science with precision immunotherapy.
